Somaglutide is a long-acting glucagon-like peptide 1 (GLP-1) analogue and agonist of the GLP-1 receptor. It has potential therapeutic efficacy for type 2 diabetes mellitus (T2DM).

For drug weight reduction, the US FDA has approved a total of five classes of weight loss drugs, including Liraglutide. Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue, which has not only hypoglycemic but also cardiovascular protective effects.

Large-scale clinical studies such as LEADER and SUSTAIN 6 have demonstrated that these drugs can significantly reduce weight and cardiovascular risk in diabetic patients.

Recently, the STEP-2 trial also found that patients with type 2 diabetes who received weekly injections of sommarlutide lost an average of about 20 pounds.

The study showed that two-thirds of patients with type 2 diabetes who were given weekly injections of 2.4 mg of sommarlutide lost at least 5% of their body weight and significantly improved blood sugar control.

In addition, more than a quarter of patients lost 15 percent of their body weight. This weight loss effect exceeds that of any current hypoglycemic medication.